WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004008152) METHOD FOR SCREENING EBNA-1 INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/008152    International Application No.:    PCT/JP2003/008972
Publication Date: 22.01.2004 International Filing Date: 15.07.2003
IPC:
G01N 33/569 (2006.01)
Applicants: FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Dosho-machi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP) (For All Designated States Except US).
YANAGI, Kazuo [JP/JP]; (JP) (For US Only).
ITOU, Sayuri [JP/JP]; (JP) (For US Only)
Inventors: YANAGI, Kazuo; (JP).
ITOU, Sayuri; (JP)
Agent: SHIMIZU, Hatsushi; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki 300-0847 (JP)
Priority Data:
60/395,619 15.07.2002 US
Title (EN) METHOD FOR SCREENING EBNA-1 INHIBITORS
(FR) PROCEDE DE CRIBLAGE D'INHIBITEURS DE LA PROTEINE EBNA-1
Abstract: front page image
(EN)The present application provides a method for screening for inhibitors that block the interaction between EBNA-1 and host cellular replication machinery. In the present invention, the inhibitor is selected based its ability to inhibit the localization of EBNA-1 in relation to chromatin in the cells. The candidates selected by the method are useful for therapeutic agent for treating a latent infection of Epstein-Barr Virus (EBV).
(FR)L'invention concerne un procédé de criblage d'inhibiteurs bloquant l'interaction entre la protéine EBNA-1 et le mécanisme de réplication cellulaire d'un hôte. Selon la présente invention, l'inhibiteur est sélectionné en fonction de sa capacité à inhiber la localisation de la protéine EBNA-1 par rapport à la chromatine dans les cellules. Les inhibiteurs potentiels sélectionnés au moyen dudit procédé peuvent constituer des agents thérapeutiques servant à traiter une infection latente par le virus d'Epstein-Barr (EBV).
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)